Biomarkers for physical frailty and sarcopenia: State of the science and future developments

Journal of Cachexia, Sarcopenia and Muscle

Volumn 6, Issue 4, 2015, Pages 278-286

  Calvani, Riccardo ^a   Marini, Federico ^b   Cesari, Matteo ^c,d   Tosato, Matteo ^a   Anker, Stefan D ^e   Von Haehling, Stephan ^e   Miller, Ram R ^f   Bernabei, Roberto ^a   Landi, Francesco ^a   Marzetti, Emanuele ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Ageing; Circulating markers; Disability; Imaging; Multivariate modelling; Physical performance

Indexed keywords

BIOLOGICAL MARKER;

EMOTION; GERIATRIC DISORDER; HUMAN; METHODOLOGY; PHYSICAL FRAILTY; PRIORITY JOURNAL; REVIEW; SARCOPENIA; VALIDATION STUDY;

EID: 84951560109     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12051     Document Type: Review

References (78)

1. Rosemberg IH. Summary comments: epidemiological and methodological problems in determining nutritional status of older persons. Am J Clin Nutr 1989;50:1231–1233.
2. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995;332:556–561.
3. Cruz-Jentoft AJ, Landi F, Schneider SM, Zuniga C, Arai H, Boirie Y et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014;43:748–759.
4. Rodriguez-Manas L, Feart C, Mann G, Vina J, Chatterji S, Chodzko-Zajko W et al. Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition—consensus conference project. J Gerontol A Biol Sci Med Sci 2013;68:62–67.
5. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013;381:752–762.
6. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56: M146–M156.
7. Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E. Sarcopenia and physical frailty: two sides of the same coin. Front Aging Neurosci 2014;6:192.
8. Marzetti E, Calvani R, Bernabei R, Leeuwenburgh C. Apoptosis in skeletal myocytes: a potential target for interventions against sarcopenia and physical frailty – a mini-review. Gerontology 2012;58: 99–106.
9. Landi F, Calvani R, Cesari M, Tosato M, Martone AM, Bernabei R et al. Sarcopenia as the biological substrate of physical frailty. Clin Geriatr Med 2015.
10. Marzetti E, Buford TW, Bernabei R. Is misuse of the sarcopenia due to a lack of biomarkers? J Appl Physiol 2012;113:680.
11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89–95.
12. Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA et al. Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle 2012;3: 181–190.
13. Marzetti E. Imaging, functional and biological markers for sarcopenia: the pursuit of the golden ratio. J Frailty Aging 2012;1: 97–98.
14. Cummings SR, Studenski S, Ferrucci L. A diagnosis of dismobility—giving mobility clinical visibility: a Mobility Working Group recommendation. JAMA 2014;311: 2061–2062.
15. Studenski S, Perera S, Wallace D, Chandler JM, Duncan PW, Rooney E et al. Physical performance measures in the clinical setting. J Am Geriatr Soc 2003;51:314–322.
16. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85–M94.
17. Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M et al. Gait speed and survival in older adults. JAMA 2011;305:50–58.
18. Rantanen T, Guralnik JM, Foley D, Masaki K, Leveille S, Curb JD et al. Midlife hand grip strength as a predictor of old age disability. JAMA 1999;281:558–560.
19. Scharf G, Heineke J. Finding good biomarkers for sarcopenia. J Cachexia Sarcopenia Muscle 2012;3:145–148.
20. Palus S, von HS SJ. Muscle wasting: an overview of recent developments in basic research. J Cachexia Sarcopenia Muscle 2014;5:193–198.
21. Marzetti E, Lees HA, Wohlgemuth SE, Leeuwenburgh C. Sarcopenia of aging: underlying cellular mechanisms and protection by calorie restriction. Biofactors 2009;35:28–35.
22. Marzetti E, Lees HA, Manini TM, Buford TW, Aranda JM Jr., Calvani R et al. Skeletal muscle apoptotic signaling predicts thigh muscle volume and gait speed in community-dwelling older persons: an exploratory study. PLoS One 2012;7 e32829.
23. Joseph AM, Adhihetty PJ, Buford TW, Wohlgemuth SE, Lees HA, Nguyen LM et al. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. Aging Cell 2012;11:801–809.
24. Calvani R, Joseph AM, Adhihetty PJ, Miccheli A, Bossola M, Leeuwenburgh C et al. Mitochondrial pathways in sarcopenia of aging and disuse muscle atrophy. Biol Chem 2013;394:393–414.
25. Marzetti E, Wohlgemuth SE, Lees HA, Chung HY, Giovannini S, Leeuwenburgh C. Age-related activation of mitochondrial caspase-independent apoptotic signaling in rat gastrocnemius muscle. Mech Ageing Dev 2008;129:542–549.
26. Hofer T, Marzetti E, Xu J, Seo AY, Gulec S, Knutson MD et al. Increased iron content and RNA oxidative damage in skeletal muscle with aging and disuse atrophy. Exp Gerontol 2008;43:563–570.
27. Altun M, Besche HC, Overkleeft HS, Piccirillo R, Edelmann MJ, Kessler BM et al. Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway. J Biol Chem 2010;285:39597–39608.
28. Balagopal P, Rooyackers OE, Adey DB, Ades PA, Nair KS. Effects of aging on in vivo synthesis of skeletal muscle myosin heavychain and sarcoplasmic protein in humans. Am J Physiol 1997;273:E790–E800.
29. Marzetti E, Calvani R, Cesari M, Buford TW, Lorenzi M, Behnke BJ et al. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. Int J Biochem Cell Biol 2013;45:2288–2301.
30. Nedergaard A, Karsdal MA, Sun S, Henriksen K. Serological muscle loss biomarkers: an overview of current concepts and future possibilities. J Cachexia Sarcopenia Muscle 2013;4:1–17.
31. Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys WG et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2004;59:242–248.
32. Tiainen K, Hurme M, Hervonen A, Luukkaala T, Jylha M. Inflammatory markers and physical performance among nonagenarians. J Gerontol A Biol Sci Med Sci 2010;65:658–663.
33. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men andwomen: the Health ABC Study. J Gerontol A Biol Sci Med Sci 2002;57:M326–M332.
34. Verghese J, Holtzer R, Oh-Park M, Derby CA, Lipton RB, Wang C. Inflammatory markers and gait speed decline in older adults. J Gerontol A Biol Sci Med Sci 2011;66:1083–1089.
35. Penninx BW, Kritchevsky SB, Newman AB, Nicklas BJ, Simonsick EM, Rubin S et al. Inflammatory markers and incident mobility limitation in the elderly. J Am Geriatr Soc 2004;52:1105–1113.
36. Penninx BW, Pahor M, Cesari M, Corsi AM, Woodman RC, Bandinelli S et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 2004;52: 719–724.
37. Visser M, Kritchevsky SB, Newman AB, Goodpaster BH, Tylavsky FA, Nevitt MC et al. Lower serum albumin concentration and change in muscle mass: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005;82:531–537.
38. Voznesensky M, Walsh S, Dauser D, Brindisi J, Kenny AM. The association between dehydroepiandosterone and frailty in older men and women. Age Ageing 2009; 38:401–406.
39. Araujo AB, Travison TG, Bhasin S, Esche GR, Williams RE, Clark RV et al. Association between testosterone and estradiol and age-related decline in physical function in a diverse sample of men. J Am Geriatr Soc 2008;56:2000–2008.
40. Onder G, Liperoti R, Russo A, Soldato M, Capoluongo E, Volpato S et al. Body mass index, free insulin-like growth factor I, and physical function among older adults: results from the ilSIRENTE study. Am J Physiol Endocrinol Metab 2006;291:E829–E834.
41. Mastaglia SR, Seijo M, Muzio D, Somoza J, Nunez M, Oliveri B. Effect of vitamin D nutritional status on muscle function and strength in healthy women aged over sixty-five years. J Nutr Health Aging 2011;15:349–354.
42. Dalal M, Ferrucci L, Sun K, Beck J, Fried LP, Semba RD. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. J Gerontol A Biol Sci Med Sci 2009;64:132–137.
43. Semba RD, Ferrucci L, Sun K, Walston J, Varadhan R, Guralnik JM et al. Oxidative stress and severe walking disability among older women. Am J Med 2007; 120:1084–1089.
44. Cesari M, Kritchevsky SB, Nicklas BJ, Penninx BW, Holvoet P, Koh-Banerjee P et al. Lipoprotein peroxidation and mobility limitation: results from the Health, Aging, and Body Composition Study. Arch Intern Med 2005;165:2148–2154.
45. Semba RD, Blaum C, Guralnik JM, Moncrief DT, Ricks MO, Fried LP. Carotenoid and vitamin E status are associated with indicators of sarcopenia among older women living in the community. Aging Clin Exp Res 2003;15:482–487.
46. Alipanah N, Varadhan R, Sun K, Ferrucci L, Fried LP, Semba RD. Low serum carotenoids are associated with a decline in walking speed in older women. J Nutr Health Aging 2009;13:170–175.
47. Marzetti E, Lorenzi M, Antocicco M, Bonassi S, Celi M, Mastropaolo S et al. Shorter telomeres in peripheral blood mononuclear cells from older persons with sarcopenia: results from an exploratory study. Front Aging Neurosci 2014;6:233.
48. Fragala MS, Jajtner AR, Beyer KS, Townsend JR, Emerson NS, Scanlon TC et al. Biomarkers of muscle quality: Nterminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults. J Cachexia Sarcopenia Muscle 2014;5:139–148.
49. Bhasin S, He EJ, Kawakubo M, Schroeder ET, Yarasheski K, Opiteck GJ et al. N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone. J Clin Endocrinol Metab 2009;94:4224–4233.
50. Chen F, Lam R, Shaywitz D, Hendrickson RC, Opiteck GJ, Wishengrad D et al. Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle 2011;2:45–56.
51. Berry SD, Ramachandran VS, Cawthon PM, Gona P, McLean RR, Cupples LA et al. Procollagen type III N-terminal peptide (P3NP) and lean mass: a cross-sectional study. J Frailty Aging 2013;2:129–134.
52. Hettwer S, Dahinden P, Kucsera S, Farina C, Ahmed S, Fariello R et al. Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients. Exp Gerontol 2013;48:69–75.
53. Drey M, Sieber CC, Bauer JM, Uter W, Dahinden P, Fariello RG et al. C-terminal Agrin Fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junction. Exp Gerontol 2013;48:76–80.
54. Stout JR, Fragala MS, Hoffman JR, Robinson EH, Mccormack WP, Townsend JR et al. C-terminal agrin fragment is inversely related to neuromuscular fatigue in older men. Muscle Nerve 2015;51:132–133.
55. Marzetti E, Calvani R, Lorenzi M, Marini F, D’Angelo E, Martone AM et al. Serum levels of C-terminal agrin fragment (CAF) are associated with sarcopenia in older hip fractured patients. Exp Gerontol 2014;60C:79–82.
56. Stephan A, Mateos JM, Kozlov SV, Cinelli P, Kistler AD, Hettwer S et al. Neurotrypsin cleaves agrin locally at the synapse. FASEB J 2008;22:1861–1873.
57. Butikofer L, Zurlinden A, Bolliger MF, Kunz B, Sonderegger P. Destabilization of the neuromuscular junction by proteolytic cleavage of agrin results in precocious sarcopenia. FASEB J 2011;25:4378–4393.
58. Ogawa K, Kim HK, Shimizu T, Abe S, Shiga Y, Calderwood SK. Plasma heat shock protein 72 as a biomarker of sarcopenia in elderly people. Cell Stress Chaperones 2012; 17:349–359.
59. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435–442.
60. Robinson MB, Tidwell JL, Gould T, Taylor AR, Newbern JM, Graves J et al. Extracellular heat shock protein 70: a critical component for motoneuron survival. J Neurosci 2005;25: 9735–9745.
61. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012; 8:457–465.
62. Clark RV, Walker AC, O’Connor-Semmes RL, Leonard MS, Miller RR, Stimpson SA et al. Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans. J Appl Physiol (1985) 2014;116: 1605–1613.
63. Stimpson SA, Leonard MS, Clifton LG, Poole JC, Turner SM, Shearer TW et al. Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D-creatine dilution method. J Cachexia Sarcopenia Muscle 2013;4: 217–223.
64. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115:949–952.
65. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics—a review in human disease diagnosis. Anal Chim Acta 2010;659:23–33.
66. Jackson JE. A User’s Guide to Principal Components. New York: John Wiley and Sons; 1991.
67. Smilde AK, Jansen JJ, Hoefsloot HC, Lamers RJ, van der Greef J, Timmerman ME. ANOVA-simultaneous component analysis (ASCA): a new tool for analyzing designed metabolomics data. Bioinformatics 2005; 21:3043–3048.
68. Bevilacqua M, Bucci R, Magrì AL, Magrì R, Nescatelli R, Marini F. Classification and class-modeling. In Marini F, ed. Chemometrics in Food Chemistry. Oxford: Elsevier; 2013. p171–233.
69. Szymanska E, Saccenti E, Smilde AK, Westerhuis JA. Double-check: validation of diagnostic statistics for PLS-DA models in metabolomics studies. Metabolomics 2012;8:3–16.
70. Marzetti E, Landi F, Marini F, Cesari M, Buford TW, Manini TM et al. Patterns of circulating inflammatory biomarkers in older persons with varying levels of physical performance: a Partial Least Squares- Discriminant Analysis (PLS-DA) approach. Front Med 2014;1:27.
71. Stenholm S, Tiainen K, Rantanen T, Sainio P, Heliovaara M, Impivaara O et al. Longterm determinants of muscle strength decline: prospective evidence from the 22-year mini-Finland follow-up survey. J Am Geriatr Soc 2012;60:77–85.
72. Sayer AA, Syddall HE, Gilbody HJ, Dennison EM, Cooper C. Does sarcopenia originate in early life? Findings from the Hertfordshire cohort study. J Gerontol A Biol Sci Med Sci 2004;59:M930–M934.
73. Kuh D, Hardy R, Butterworth S, Okell L, Richards M, Wadsworth M et al. Developmental origins of midlife physical performance: evidence from a British birth cohort. Am J Epidemiol 2006;164:110–121.
74. Kuh D, Hardy R, Butterworth S, Okell L, Wadsworth M, Cooper C et al. J Gerontol A Biol Sci Med Sci 2006;61:702–706.
75. Calvani R, Miccheli A, Landi F, Bossola M, Cesari M, Leeuwenburgh C et al. Current nutritional recommendations and novel dietary strategies to manage sarcopenia. J Frailty Aging 2013;2:38–53.
76. Kourti T, MacGregor JF. Process analysis, monitoring and diagnosis, using multivariate projection methods. Chemometr Intell Lab Syst 2014;28:3–21.
77. Jansen JJ, Hoefsloot HC, Boelens HF, van der Greef J, Smilde AK. Analysis of longitudinal metabolomics data. Bioinformatics 2004;20:2438–2446.
78. Eliot TS. Collected Poems. New York: Harcourt Brace Jovanovich; 1963.